Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
				a single therapy in the treatment of the above infections. However under the appropriate conditions it may be used with an aminoglycoside antibiotic or metronidazole. In certain situations where mixed aerobic and anaerobic infection is suspected such as peritonitis, aspiration pneumonia, abscesses in the lung, pelvis and brain or are likely to occur, for example in association with colorectal or gynaecological surgery, cefuroxime can be administered with metronidazole. Most of these infections will respond to an intravenous regimen of cefuroxime (750mg) plus metronidazole injection (500mg/100ml) administered eight hourly. In more severe or well established mixed infections, an intravenous regimen of cefuroxime (1.5g.) plus metronidazole injection (500mg/100ml) eight hourly may be indicated. For the prophylaxis of infection in surgery (eg colorectal and gynaecological) a single dose of 1.5g ceftiroxime plus metronidazole injection (500mg/100ml) is appropriate. Alternatively, this may be followed by two 750mg doses of cefuroxime plus metronidazole. Bacteriology Cefuroxime is highly active against Staphylococcus aureus, including strains which are resistant to penicillin (but not the rare methicillin-resistant strains), Staph. epidermis, Haemophilus	
				Staph. epidermis, Haemophilus influenzae, Klebsiella spp., Enterobacter spp., Streptococcus pydgenes, Escherichia coli, Str. milis (viridans group), clostridium spp., Proteus mirabilis, Pr. rettgeri, salmonella typhi, S. Typhimurium and other salmonella spp., Shigella spp., Neisseria spp. (including *lactarnase producing strains of n. Gonorrhoea) and bordetelia pertussis. It is also moderately active against strains	
04569/0279	Generics (UK) Ltd	Cefuroxime Injection 750mg	Cefuroxime Sodium 789.000mg	Prescription Only Medicine See PL4569/0273	12th April 1996
04569/0280	Generics (UK) Ltd	Cefuroxime Injection 1.5g	Cefuroxime Sodium 1578.000mg	Prescription Only Medicine See PL4569/0273	12th April 1996
04946/0016	Pharmachemie BV	Doxorubin 0.2%	Doxorubicin Hydrochloride 2.000mg	Prescription Only Medicine For the treatment of acute lymphocytic leukaemia, except acute lymphatic leukaemia of low risk in children, acute myeloid leukaemia, Hodgkin- and non- Hodgkin lymphomas, osteosarcoma, Ewing sarcoma, adult soft tissue sarcoma, metastatic mammacarcinoma, gastric carcinoma, small-cell lung cancer, neuroblastoma, Wilms tumour and bladder carcinoma. Doxorubicin may be used intravesically as single agent for treatment and prophylaxis of superficial bladder carcinoma.	4th January 1996
04984/0026	Leiras OY	Oxybutynin Hydrochloride 5mg Tablets Leiras	Oxybutynin Hydrochloride 5.100mg	Prescription Only Medicine Urinary incontinence, urgency and frequency in unstable bladder conditions due either to idiopathic detrusor instability or neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as spina bifida and multiple sclerosis. Children over 5 years of age: in addition to neurogenic bladder disorders oxybutynin may be used in nocturnal enuresis in conjunction with non-pharmacological therapy where	281h March 1996